1623 Farnam Appoints Bill Severn as CEO and President
Industry luminary appointed to top role at premier Midwest data center and interconnection hub, carrying forward growth and service expansion.
As a long-time industry leader, Severn has played a key role in 1623 Farnam's technological acceleration and ongoing growth since 2019 as Operating Partner for parent company BERKS Group. Most recently, Severn spearheaded a 3MW power deployment, expanding capacity at 1623 Farnam to support advanced hyperscale peering and colocation demands today and in the future.
"I've had the pleasure of working within and supporting the 1623 Farnam ecosystem for more than five years now, and I am proud to take on this new title as we grow and support our customers' innovation," said Severn.
Severn is also Executive Vice President at BERKS Group, where he leads business development efforts in technology infrastructure. In addition to his current roles, Severn has deep industry experience in fiber networks, cable, broadband, data storage and cloud services. He has previously served on the board of OnLine Tech, as well as in the role of COO of NPG Cablevision.
"This appointment is a natural fit based on Bill's deep expertise and proven leadership both in the industry and at 1623 Farnam. His work positioning the company as the premier Midwest data center and driving critical growth at the Omaha IX have not only put the organization on the path to success, but continue to bring increasing levels of value to customers in the growing 1623 Farnam ecosystem," said
1623 Farnam and its on-site Omaha IX are located in a strategic, centralized spot in the
To learn more about 1623 Farnam, visit 1623farnam.com.
View original content:https://www.prnewswire.com/news-releases/1623-farnam-appoints-bill-severn-as-ceo-and-president-302036674.html
SOURCE 1623 Farnam, LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Insurance Agent Nick Hogan Explains What First-Time Homeowners Often Miss About Homeowners Insurance in HelloNation
- Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
- Phase III MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for Small-Cell Lung Cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share